47
Participants
Start Date
March 3, 2010
Primary Completion Date
September 26, 2012
Study Completion Date
February 27, 2013
PF-04449913
Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
U.O. di Ematologia, Bologna
UCSD Medical Center - La Jolla, La Jolla
Moores UCSD Cancer Center, La Jolla
UCSD Medical Center - Hillcrest, San Diego
The University of Texas M.D. Anderson Cancer Center, Houston
University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle
Lead Sponsor
Pfizer
INDUSTRY